London, Ontario, Canada, October 11, 2024 – Alimentiv Inc. (“Alimentiv”) is pleased to announce four poster presentations at the United European Gastroenterology (UEG) conference taking place October 12-15, 2024, at the Reed Messe Wien Exhibition Congress Center, in Vienna, Austria.

Alimentiv is the leading contract research organization (CRO) for gastroenterology (GI) clinical trial management and medical imaging since 1986. As a global CRO offering end-to-end clinical research solutions, Alimentiv is committed to improving trial outcomes and accelerating drug development timelines. As a globally recognized leader in medical imaging solutions, outcome measures development, and multi-center trials, Alimentiv partners with pharmaceutical and biotechnology companies and medical research centers to deliver innovative solutions and support for clinical development programs.

This year, at UEG Week 2024, Alimentiv will highlight its capabilities in delivering comprehensive, innovative GI research solutions.

Dr. Vipul Jairath, Principal Investigator for the VERDICT study, will be presenting updates on the Alimentiv and Takeda collaborative VERDICT trial, “Target Achievement After 32 Weeks of Vedolizumab Treatment in Patients With Moderate to Severe Ulcerative Colitis: An Interim Analysis From the VERDICT Trial.” The objectives of the VERDICT study are to identify the optimal treatment target for patients with moderate-to-severely active ulcerative colitis (UC) and to close an area of unmet need in the medical management of patients with UC.

The VERDICT study outlines a treatment approach for UC that prioritizes the early use of vedolizumab and achieves a specific target (either endoscopic remission, histo-endoscopic mucosal improvement, or symptomatic remission), without the need for corticosteroids. The primary aim is to determine if a treatment target of corticosteroid-free symptomatic, endoscopic, and histologic remission is better than achieving only corticosteroid-free symptomatic remission in patients with moderate-to-severely active UC. The research also aims to find specific biomarkers that can help predict which patients will benefit most from the drug and who might need alternative treatments. The phase 4 study successfully completed recruitment of 672 patients on May 6, 2024 and participants were randomized across 65 sites in 10 countries. The study is expected to be completed in 2026.

Poster sessions include:

Interventions for the Management of Complications in Patients With Inflammatory Bowel Disease and Permanent Ileostomy for the Endotrial Consortium: A Systematic Review | Poster MP270 | Presenter: Dr. Virginia Solitano

Management of Complications in Patients With an Ileostomy: An Umbrella Review of Systematic Reviews for the Endotrial Consortium | Poster PP0598 | Presenter: Dr. Virginia Solitano

Evaluating Placebo Rates in Eosinophilic Esophagitis Randomized Controlled Trials: A Systematic Review and Meta-Analysis | Poster MP484 | Presenter: Dr. Angelica Rivas

Target Achievement After 32 Weeks of Vedolizumab Treatment in Patients With Moderate to Severe Ulcerative Colitis: An Interim Analysis From the VERDICT Trial | Poster PP1024 | Presenter: Dr. Vipul Jairath

See the full schedule


Visit Alimentiv at Booth #57 to explore how Alimentiv’s experts can partner with you to achieve your project goals.

About Alimentiv Inc.

Alimentiv is a leading specialty GI-focused CRO, advancing frontiers of gastrointestinal (GI) clinical trials and medical research since 1986. As a global CRO offering clinical, medical imaging and precision medicine services, Alimentiv partners with pharmaceutical and biotechnology industries to advance the development of novel therapies and accelerate their time to market. Alimentiv is headquartered in London, Ontario, Canada, with a global footprint across its operations in Canada, the United States, Europe, Asia-Pacific, and Latin America.